Dogwood Therapeutics, Inc.
Business
Dogwood Therapeutics is a pre-revenue, development-stage biopharmaceutical company focused on developing non-opioid pain treatments and therapies for neuropathy. The company's lead program, Halneuron®, a Nav1.7 sodium channel modulator derived from tetrodotoxin, is in Phase 2b clinical trials for chemotherapy-induced neuropathic pain; the recently licensed SP16 program targets chemotherapy-induced peripheral neuropathy via cell signaling mechanisms. Additional pipeline candidates include IMC-1 and IMC-2, antiviral combination therapies for fibromyalgia and Long-COVID. Commercialization is expected through partnerships with pharmaceutical companies targeting anesthesiologists, oncologists, and primary care physicians.
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 22 | 4 | 2 | 8 | 11 | |
| General and administrative expenses | 6 | 9 | 4 | 4 | 5 | |
| Total operating expenses | 28 | 12 | 5 | 12 | 16 | |
| Loss from operations | −28 | −12 | −5 | −12 | −16 | |
| Loss on debt conversion with related party | −6 | — | — | — | — | |
| Loss on fixed asset disposal | −2,731 | — | — | — | — | |
| Interest income (expense), net | 96,938 | −92,192 | 150,904 | — | — | |
| Exchange loss, net | −27,916 | −30,787 | — | — | — | |
| Total other expense | −6 | −122,979 | 150,904 | 67,475 | −319,328 | |
| Loss before income taxes | −34 | −12 | −5 | −12 | −16 | |
| Deferred income tax (expense) benefit | −221,096 | 503 | — | — | — | |
| Net loss | −34 | −12 | −5 | −12 | −16 | |
| Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | −1 | −514,105 | — | — | — | |
| Net loss attributable to common stockholders | −36 | −13 | −5 | — | — | |
| Net loss per common share, basic (in dollars per share) | −7.13 | −12.52 | −7.05 | −1.11 | −1.92 | |
| Net loss per common share, diluted (in dollars per share) | −7.13 | −12.52 | −7.05 | −1.11 | −1.92 | |
| Weighted average number of shares outstanding - basic (in shares) | 5 | 1 | 751,071 | 11 | 8 | |
| Weighted average number of shares outstanding - diluted (in shares) | 5 | 1 | 751,071 | 11 | 8 | |
| Foreign currency translation adjustment | 3 | −4 | — | — | — | |
| Comprehensive loss | −31 | −16 | −5 | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 15 | 3 | 7 | 14 | |
| Prepaid expenses and other current assets | 2 | 2 | 848,496 | 1 | 2 | |
| Total current assets | 8 | 17 | 4 | 8 | 16 | |
| Property and equipment, net | 12,754 | 16,811 | — | — | — | |
| Right-of-use assets | 163,140 | 205,837 | — | — | — | |
| Prepaid expenses, long-term | 19,037 | 18,133 | — | — | — | |
| Goodwill | 12 | 12 | — | — | — | |
| Intangible assets | 69 | 66 | — | — | — | |
| Deferred issuance costs | 158,956 | — | — | — | — | |
| Total assets | 90 | 94 | 4 | 8 | 16 | |
| Accounts payable | 760,945 | 1 | 111,913 | 573,164 | 353,863 | |
| Accrued expenses | 2 | 2 | 246,635 | 470,098 | 921,760 | |
| Lease liability, current portion | 56,841 | 49,696 | — | — | — | |
| Total current liabilities | 3 | 3 | 358,548 | 1 | 1 | |
| Debt with related party, net of issuance costs | — | 15 | — | — | — | |
| Lease liability, long-term portion | 105,763 | 154,885 | — | — | — | |
| Deferred tax liability | 12 | 11 | 0 | — | — | |
| Total liabilities | 15 | 30 | 358,548 | 1 | 1 | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Series A Non-Voting Convertible Preferred Stock, $0.0001 par value; 2,104 shares authorized and 2,103.1494 shares issued and no shares outstanding at December 31, 2025 and 2,270 shares authorized and 2,213.8044 shares issued and outstanding at December 31, 2024 | — | 74 | — | — | — | |
| Common stock, $0.0001 par value; 43,000,000 shares authorized; 29,751,234 and 29,743,516 shares issued and outstanding at December 31, 2025, respectively; and 1,339,896 and 1,332,178 shares issued and outstanding at December 31, 2024, respectively | 2,974 | 133 | 77 | 1,833 | 833 | |
| Additional paid-in capital | 184 | 68 | 66 | 63 | 58 | |
| Accumulated deficit | −108 | −74 | −61 | −56 | −44 | |
| Accumulated other comprehensive loss | −587,039 | −4 | — | — | — | |
| Stockholders' equity before treasury stock | 75 | −10 | 4 | 7 | — | |
| Less: Treasury stock, 7,718 shares of common stock at cost | −299,128 | −299,128 | −299,128 | — | — | |
| Total stockholders' equity (deficit) | 75 | −10 | 4 | 7 | 15 | |
| Total liabilities, Series A Non-Voting Convertible Preferred Stock and stockholders' equity (deficit) | 90 | 94 | 4 | 8 | 16 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −34 | −12 | −5 | −12 | −16 | |
| Loss on foreign exchange | 27,916 | 30,787 | — | — | — | |
| Amortization of loan costs | 52,373 | 58,432 | — | — | 0 | |
| Depreciation | 2,063 | 12,177 | — | — | — | |
| Reduction in carrying amount of right-of-use asset | 66,115 | — | — | — | — | |
| Acquisition of license for research and development | 12 | — | — | — | — | |
| Non-cash transaction costs | — | 4 | — | — | — | |
| Share-based compensation expense | 355,642 | 476,021 | 619,972 | 582,659 | 322,881 | |
| Increase in prepaid expenses and other current assets | −208,687 | −498,717 | 490,268 | 429,739 | −91,138 | |
| (Decrease) increase in accounts payable | −532,607 | 219,888 | −461,251 | 219,301 | 270,007 | |
| Increase (decrease) in accrued expenses and other liabilities | 608,290 | −302,439 | −223,463 | — | — | |
| Net cash used in operating activities | −16 | −9 | −5 | −11 | −16 | |
| Cash acquired through the acquisition of Pharmagesic | — | 4 | — | — | — | |
| Net cash provided by investing activities | — | 4 | — | — | — | |
| Proceeds from public offering of common stock, net of offering costs | 4 | 1 | — | — | — | |
| Proceeds from loan with related party, net of fees | 3 | 15 | — | — | — | |
| Payout of fractional shares with reverse stock split | — | −351 | — | — | — | |
| Proceeds from issuance of shares on ATM, net of cash fees paid | 86,366 | — | 1 | — | — | |
| Cash payment of issuance costs | −53,805 | — | — | — | — | |
| Net cash provided by financing activities | 7 | 17 | 1 | 4 | −97,604 | |
| Net (decrease) increase in cash | −8 | 12 | −4 | −7 | −16 | |
| Effect of foreign currency translation on cash and cash equivalents | 10,640 | −144,592 | — | — | — | |
| Issuance costs included in accounts payable and accrued expenses | 106,266 | — | — | — | — | |
| Conversion of debt with related party into Series A-1 Non-Voting Convertible Preferred Stock | 20 | — | — | — | — | |
| Conversion of accrued interest on debt with related party into Series A-1 Non-Voting Convertible Preferred Stock | 426,891 | — | — | — | — | |
| Conversion of Series A Non-Voting Convertible Preferred Stock from temporary equity to permanent equity | 6 | — | — | — | — | |
| Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | 1 | 514,105 | — | — | — | |
| Preferred stock issued in connection with License Agreement | 10 | — | — | — | — | |
| Common stock issued in connection with License Agreement | 2 | — | — | — | — | |
| Conversion of preferred stock into common stock | 110 | — | — | — | — | |
| Preferred stock issued in connection with acquisition of Pharmagesic | — | 70 | — | — | — | |
| Common stock issued in connection with acquisition of Pharmagesic | — | 893,093 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Dogwood Therapeutics, Inc.'s CIK number?
Dogwood Therapeutics, Inc.'s SEC CIK number is 0001818844 (1818844). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Dogwood Therapeutics, Inc.'s SEC filings?
All of Dogwood Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Dogwood Therapeutics, Inc. last report earnings?
Dogwood Therapeutics, Inc. (DWTX) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-060747). This is Dogwood Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Dogwood Therapeutics, Inc.'s most recent earnings 8-K?
Dogwood Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001104659-26-060747. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Dogwood Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →